Results 241 to 250 of about 93,675 (311)

Automated Feature Extraction and Classification of Submerged Cultural Heritage Assets in the Puck Lagoon via Multisensor Remote Sensing

open access: yesArchaeological Prospection, EarlyView.
ABSTRACT This study presents a strong framework for the detection and classification of Submerged Cultural Heritage Assets (SCHA) in shallow marine environments using the integration of multibeam echosounder and airborne LiDAR bathymetry with object‐based image analysis and fuzzy logic–based classification.
Łukasz Janowski   +4 more
wiley   +1 more source

American College of Rheumatology Guidance Statement for Diagnosis and Management of VEXAS Developed by the International VEXAS Working Group Expert Panel

open access: yesArthritis &Rheumatology, EarlyView.
Objective Vacuoles E1 enzyme X‐linked autoinflammatory somatic syndrome (VEXAS) is a recently identified rare genetic disorder associated with somatic mutations in the UBA1 gene. VEXAS presents with a combination of inflammatory and hematologic manifestations, leading to increased morbidity and mortality.
Arsene Mekinian   +111 more
wiley   +1 more source

Comparative Efficacy and Safety of Anakinra and Canakinumab in Patients With VEXAS Syndrome: An International Multicenter Study

open access: yesArthritis &Rheumatology, EarlyView.
Objective The aim of this study was to compare differences in clinical response, drug survival, and adverse event rates between anakinra and canakinumab in VEXAS (vacuoles, E1 enzyme, X‐linked, autoinflammatory, somatic) syndrome. Methods This multicenter international study includes patients with VEXAS from France, Israel, and Italy treated with ...
Tali Eviatar   +35 more
wiley   +1 more source

Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: the Randomized, Phase 3, TULIP‐SC Study

open access: yesArthritis &Rheumatology, Accepted Article.
Objective The multinational, phase 3, double‐blind, placebo‐controlled TULIP‐SC trial evaluated the efficacy and safety of subcutaneous anifrolumab in adults who have moderate‐to‐severe SLE activity, despite receiving standard therapy. Methods Adults with SLE received subcutaneous anifrolumab 120 mg or placebo once weekly for 52 weeks (1:1 ...
Susan Manzi   +12 more
wiley   +1 more source

The lack of legal protections in the United States to prevent commercializing the dead for education and research: Consequences and risks to anatomists

open access: yesAnatomical Sciences Education, EarlyView.
Abstract A lack of minimum legal standards for body donation programs undermines recent strides by anatomy professionals to promote ethical best practices in the United States (US). In particular, the commercialization of the dead by nontransplant tissue banks poses a risk to the public trust in academic body donation programs.
Laura E. Johnson
wiley   +1 more source

“You're this person who's providing light”: Embodied responses to information loss and transition within LGBTQIA+ communities

open access: yesJournal of the Association for Information Science and Technology, EarlyView.
Abstract This paper reports on findings from 15 semi‐structured interviews with LGBTQIA+ individuals within the United States who have experienced the loss of one or more LGBTQIA+ information spaces. The paper specifically focuses on how such losses occurred and the information transitions experienced by the participants in response to this loss ...
Travis L. Wagner, Vanessa L. Kitzie
wiley   +1 more source

Market potential of biobased chemicals: a qualitative network analysis of adoption dynamics in South Africa’s bioeconomy

open access: yesBiofuels, Bioproducts and Biorefining, EarlyView.
Abstract The premise of a bioeconomy is the replacement of nonrenewable and unsustainable fossil‐derived resources and associated technologies with more sustainable alternatives. The adoption of biobased chemicals contributes toward the growth of a bioeconomy and is dependent on market and industry requirements.
Prisha Mandree   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy